Integrated care to improve biopsychosocial outcomes after early liver transplant for alcohol-related liver disease
Official title: 2/4-The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopschosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease
Funded at Columbia University Health Sciences · NIH-11169937 · Data updated 2026-11-12
The team tests whether combining alcohol-use disorder treatment with transplant care helps people with alcohol-related liver disease who receive early liver transplants stay sober and do better after surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $434,374 |
| NIH project number | 5R01AA030958-03 |
| Project ID | NIH-11169937 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with alcohol-associated liver disease who are being evaluated for or receiving an early liver transplant (typically with less than six months of abstinence) are the intended candidates.
✕Less likely to help
People without alcohol-related liver disease, those not undergoing transplant evaluation, or those already stably abstinent long before evaluation are unlikely to be eligible or benefit directly from this project.
What this research studies
You would join a multicenter effort that follows people with alcohol-associated liver disease who are evaluated for early liver transplant. The project collects medical records plus standardized questionnaires about mental health, alcohol use, social supports, and other biopsychosocial factors before and after transplant. Researchers will build risk prediction models for key patient-centered outcomes and compare outcomes across centers with different levels of integrated AUD and transplant care. Patient and stakeholder input is included to make sure findings apply across diverse racial, cultural, and socioeconomic groups.
Why it matters
Potential benefit: If successful, this work could help more people maintain sobriety, improve survival and quality of life after transplant, and guide fairer access to early liver transplantation.
How similar studies have gone: Retrospective studies suggest acceptable outcomes for early liver transplant in alcohol-associated hepatitis, but prospective, multicenter testing of integrated addiction and transplant care is largely new.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Verna, Elizabeth Clarice — Columbia University Health Sciences
- Study coordinator: Verna, Elizabeth Clarice
Related research
Other NIH-funded projects on the same topics.
-
Targeting a specific CD38 form to protect livers from injury after transplant
A new approach tests a selective drug to protect donor livers from injury during transplant, potentially increasing usable organs and improving transplant outcomes.
-
Regulatory dendritic cell therapy to reduce immunosuppressive drugs after liver transplant
A new approach using donor-derived regulatory dendritic cells is being tested to help adults who receive a liver transplant live without relying on traditional immunosuppressive drugs.
-
HOPE liver transplant: reducing infections and cancer risk for HIV-positive recipients
This grant aims to better understand why HIV-positive liver transplant recipients face higher infection and cancer risks and to improve safety and outcomes for these patients.
-
Early liver transplant decisions for severe alcohol-related liver disease
A large study follows adults with severe alcohol-related liver disease to understand how to best select and manage patients for early liver transplantation.
-
Early Liver Transplant for Severe Alcoholic Hepatitis
A hospital-based program is studying whether offering an early liver transplant to patients with severe alcoholic hepatitis can save lives when standard medical treatment fails.
-
Early liver transplant for severe alcoholic hepatitis (SAH) to save lives
A Johns Hopkins program is testing whether giving an early liver transplant to patients with severe alcoholic hepatitis who can’t be helped by standard treatments can save lives and reduce relapse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.